Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

infusystem holdings inc - INFU

INFU

Close Chg Chg %
8.71 -0.18 -2.01%

Closed Market

8.54

-0.18 (2.01%)

Volume: 124.70K

Last Updated:

Jan 15, 2026, 3:59 PM EDT

Trade Now

Company Overview: infusystem holdings inc - INFU

INFU Key Data

Open

$8.70

 Day Range

8.48 - 8.70

52 Week Range

4.66 - 11.04

 Market Cap

$177.33M

Shares Outstanding

20.34M

 Public Float

18.32M

Beta

1.68

 Rev. Per Employee

N/A

P/E Ratio

32.53

 EPS

$0.27

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

115.98K

  

INFU Performance

1 Week
 
 -0.81%
 
1 Month
 
 -6.52%
 
3 Months
 
 -4.44%
 
1 Year
 
 7.77%
 
5 Years
 
 -49.26%
 

INFU Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About infusystem holdings inc - INFU

InfuSystem Holdings, Inc. engages in the provision of healthcare services. It operates through the Patient Services and Device Solutions segments. The Patient Services segment involves the durable medical equipment, clinic-to-home health care, logistics and billing, and oncology business. The Device Solutions segment includes the sale or rent of new and pre-owned pole-mounted and ambulatory infusion pumps, treatment-related consumables, biomedical recertification, maintenance and repair services for oncology practices. The company was founded by Steven E. Watkins in August 2005 and headquartered in Rochester Hills, MI.

INFU At a Glance

InfuSystem Holdings, Inc.
3851 West Hamlin Road
Rochester Hills, Michigan 48309
Phone 1-248-291-1210 Revenue 134.86M
Industry Miscellaneous Commercial Services Net Income 2.35M
Sector Commercial Services 2024 Sales Growth 7.215%
Fiscal Year-end 12 / 2025 Employees 514
View SEC Filings

INFU Valuation

P/E Current 32.531
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 78.241
Price to Sales Ratio 1.36
Price to Book Ratio 3.125
Price to Cash Flow Ratio 8.97
Enterprise Value to EBITDA 10.975
Enterprise Value to Sales 1.578
Total Debt to Enterprise Value 0.141

INFU Efficiency

Revenue/Employee 262,375.486
Income Per Employee 4,562.257
Receivables Turnover 6.375
Total Asset Turnover 1.222

INFU Liquidity

Current Ratio 1.821
Quick Ratio 1.452
Cash Ratio 0.03

INFU Profitability

Gross Margin 50.505
Operating Margin 5.11
Pretax Margin 3.751
Net Margin 1.739
Return on Assets 2.124
Return on Equity 4.27
Return on Total Capital 2.682
Return on Invested Capital 2.709

INFU Capital Structure

Total Debt to Total Equity 51.977
Total Debt to Total Capital 34.201
Total Debt to Total Assets 26.967
Long-Term Debt to Equity 49.408
Long-Term Debt to Total Capital 32.51
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Infusystem Holdings Inc - INFU

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
102.38M 109.91M 125.78M 134.86M
Sales Growth
+5.13% +7.36% +14.44% +7.22%
Cost of Goods Sold (COGS) incl D&A
47.35M 50.94M 64.77M 66.75M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
14.63M 13.36M 12.51M 12.50M
Depreciation
10.36M 10.87M 11.52M 11.51M
Amortization of Intangibles
4.26M 2.49M 990.00K 991.00K
COGS Growth
+8.31% +7.58% +27.15% +3.06%
Gross Income
55.03M 58.98M 61.02M 68.11M
Gross Income Growth
+2.54% +7.16% +3.46% +11.62%
Gross Profit Margin
+53.75% +53.66% +48.51% +50.51%
2021 2022 2023 2024 5-year trend
SG&A Expense
52.02M 57.32M 56.93M 61.22M
Research & Development
- - - -
-
Other SG&A
52.02M 57.32M 56.93M 61.22M
SGA Growth
+15.98% +10.20% -0.68% +7.54%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 200.00K
-
EBIT after Unusual Expense
2.82M 1.65M 4.09M 6.89M
Non Operating Income/Expense
(292.00K) 76.00K 670.00K 639.00K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.27M 1.60M 2.91M 2.47M
Interest Expense Growth
+1.27% +25.89% +81.69% -15.00%
Gross Interest Expense
1.27M 1.60M 2.91M 2.47M
Interest Capitalized
- - - -
-
Pretax Income
1.26M 130.00K 1.85M 5.06M
Pretax Income Growth
-83.34% -89.66% +1,323.85% +173.31%
Pretax Margin
+1.23% +0.12% +1.47% +3.75%
Income Tax
(163.00K) 112.00K 979.00K 2.71M
Income Tax - Current - Domestic
167.00K 99.00K 245.00K 488.00K
Income Tax - Current - Foreign
(177.00K) (8.00K) 101.00K 308.00K
Income Tax - Deferred - Domestic
(153.00K) 21.00K 633.00K 1.92M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.42M 18.00K 872.00K 2.35M
Minority Interest Expense
- - - -
-
Net Income
1.42M 18.00K 872.00K 2.35M
Net Income Growth
-91.81% -98.73% +4,744.44% +168.92%
Net Margin Growth
+1.39% +0.02% +0.69% +1.74%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
1.42M 18.00K 872.00K 2.35M
Preferred Dividends
- - - -
-
Net Income Available to Common
1.42M 18.00K 872.00K 2.35M
EPS (Basic)
0.0692 0.0009 0.0415 0.1102
EPS (Basic) Growth
-91.97% -98.70% +4,511.11% +165.54%
Basic Shares Outstanding
20.52M 20.65M 21.02M 21.27M
EPS (Diluted)
0.0644 0.0008 0.0403 0.108
EPS (Diluted) Growth
-91.93% -98.76% +4,937.50% +167.99%
Diluted Shares Outstanding
22.05M 21.55M 21.65M 21.71M
EBITDA
17.64M 15.01M 16.60M 19.39M
EBITDA Growth
-22.79% -14.91% +10.54% +16.84%
EBITDA Margin
+17.23% +13.66% +13.19% +14.38%

Snapshot

Average Recommendation BUY Average Target Price 14.20
Number of Ratings 5 Current Quarters Estimate 0.026
FY Report Date 03 / 2026 Current Year's Estimate 0.412
Last Quarter’s Earnings 0.07 Median PE on CY Estimate N/A
Year Ago Earnings 0.29 Next Fiscal Year Estimate 0.47
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 5 2
Mean Estimate 0.03 0.11 0.41 0.47
High Estimates 0.08 0.12 0.50 0.50
Low Estimate -0.01 0.08 0.34 0.44
Coefficient of Variance 150.44 14.31 18.75 8.96

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 5
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Infusystem Holdings Inc - INFU

Date Name Shares Transaction Value
May 21, 2025 Richard A. Dilorio Chief Executive Officer; Director 467,434 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Kenneth D. Eichenbaum Director 39,588 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Carrie A. Lachance President and COO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Carrie A. Lachance President and COO; Director 31,250 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Carrie A. Lachance President and COO; Director 128,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Carrie A. Lachance President and COO; Director 74,228 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Carrie A. Lachance President and COO; Director 201,849 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $6.15 per share 1,241,371.35
May 21, 2025 Carrie A. Lachance President and COO; Director 207,939 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Paul A. Gendron Director 39,588 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Richard A. Dilorio Chief Executive Officer; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Richard A. Dilorio Chief Executive Officer; Director 447,925 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $6.15 per share 2,754,738.75
May 21, 2025 Beverly A. Huss Director 39,588 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Scott Alan Shuda Director 11,876 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Scott Alan Shuda Director 39,588 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Ronald T. Hundzinski Director 39,588 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Ronald T. Hundzinski Director 5,000 Open market or private purchase of non-derivative security Non-derivative transaction at $6.09 per share 30,450.00
May 21, 2025 Barry G. Steele Executive VP and CFO N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Barry G. Steele Executive VP and CFO 22,531 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Barry G. Steele Executive VP and CFO 53,518 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Barry G. Steele Executive VP and CFO 84,577 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $6.15 per share 520,148.55

Infusystem Holdings Inc in the News